This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Schwaber, M. J. Articles by Carmeli, Y. Search for Related Content PubMed PubMed Citation Articles by Schwaber, M. J. Articles by Carmeli, Y.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, April 2006, p. 1257-1262, Vol. 50, No. 4
0066-4804/06/$08.00+0     doi:10.1128/AAC.50.4.1257-1262.2006
Copyright © 2006, American Society for Microbiology. All Rights Reserved.

Clinical and Economic Impact of Bacteremia with Extended- Spectrum-ß-Lactamase-Producing Enterobacteriaceae

Division of Epidemiology,¹ Infectious Diseases Unit,³ Clinical Microbiology Laboratory, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel,⁴ Division of Infectious Diseases, Duke University Medical Center, Durham, North Carolina²

Received 11 October 2005/ Returned for modification 6 January 2006/ Accepted 17 January 2006

We studied outcomes of extended-spectrum ß-lactamase (ESBL) production in Enterobacteriaceae bacteremia. Inpatients with bacteremia caused by ESBL-producing Escherichia coli, Klebsiella spp., or Proteus spp. (cases) were compared with patients with bacteremia caused by non-ESBL producers (controls). Outcomes included mortality, mortality due to infection, length of stay (LOS), delay in appropriate therapy (DAT), discharge to a chronic care facility, and hospital cost. Ninety-nine cases and 99 controls were enrolled. Thirty-five percent of cases died, versus 18% of controls (odds ratio [OR], 2.5; 95% confidence interval [CI], 1.3 to 4.7; P = 0.01). Thirty percent of cases died due to infection, versus 16% of controls (OR, 2.3; 95% CI, 1.1 to 4.5; P = 0.03). The median LOS after bacteremia for cases was 11 days (interquartile range, 5 to 21), versus 5 days for controls (interquartile range, 3 to 9) (P < 0.001). DAT occurred in 66% of cases, versus 7% of controls (OR, 25.1; 95% CI, 10.5 to 60.2; P < 0.001). Cases were more likely than controls to be discharged to chronic care (52% versus 21%; OR, 4.0; 95% CI, 1.9 to 8.3; P < 0.001). The average hospital cost for cases was 65,509 Israeli shekels, versus 23,538 shekels for controls (P < 0.001). After adjusting for differences between groups by using multivariable analysis, ESBL production remained a significant predictor of mortality (OR, 3.6; 95% CI, 1.4 to 9.5; P = 0.008), increased LOS (1.56-fold; P = 0.001), DAT (OR, 25.1; 95% CI, 10.5 to 60.2; P < 0.001), and increased cost (1.57-fold; P = 0.003). The mean increase in equivalent cost attributable to ESBL production was $9,620. ESBL production was associated with severe adverse outcomes, including higher overall and infection-related mortality, increased LOS, DAT, discharge to chronic care, and higher costs.

This article has been cited by other articles:

• Wright, B. M., Eiland, E. H. III (2008). Current Perspectives on Extended-Spectrum Beta-Lactamase-Producing Gram-Negative Bacilli. Journal of Pharmacy Practice 21: 338-345 [Abstract]  
• Sahly, H., Navon-Venezia, S., Roesler, L., Hay, A., Carmeli, Y., Podschun, R., Hennequin, C., Forestier, C., Ofek, I. (2008). Extended-Spectrum {beta}-Lactamase Production Is Associated with an Increase in Cell Invasion and Expression of Fimbrial Adhesins in Klebsiella pneumoniae. Antimicrob. Agents Chemother. 52: 3029-3034 [Abstract] [Full Text]  
• Tumbarello, M., Sali, M., Trecarichi, E. M., Leone, F., Rossi, M., Fiori, B., De Pascale, G., D'Inzeo, T., Sanguinetti, M., Fadda, G., Cauda, R., Spanu, T. (2008). Bloodstream Infections Caused by Extended-Spectrum-{beta}-Lactamase- Producing Escherichia coli: Risk Factors for Inadequate Initial Antimicrobial Therapy. Antimicrob. Agents Chemother. 52: 3244-3252 [Abstract] [Full Text]  
• Shalit, I., Low, M., Levy, E., Chowers, M., Zimhony, O., Riesenberg, K., Bishara, J., Raz, R. (2008). Antibiotic use in 26 departments of internal medicine in 6 general hospitals in Israel: variability and contributing factors. J Antimicrob Chemother 62: 196-204 [Abstract] [Full Text]  
• Pop-Vicas, A., Strom, J., Stanley, K., D'Agata, E. M.C. (2008). Multidrug-Resistant Gram-Negative Bacteria among Patients Who Require Chronic Hemodialysis. CJASN 3: 752-758 [Abstract] [Full Text]  
• Giske, C. G., Monnet, D. L., Cars, O., Carmeli, Y., on behalf of ReAct-Action on Antibiotic Resistance, (2008). Clinical and Economic Impact of Common Multidrug-Resistant Gram-Negative Bacilli. Antimicrob. Agents Chemother. 52: 813-821 [Full Text]  
• Schwaber, M. J., Klarfeld-Lidji, S., Navon-Venezia, S., Schwartz, D., Leavitt, A., Carmeli, Y. (2008). Predictors of Carbapenem-Resistant Klebsiella pneumoniae Acquisition among Hospitalized Adults and Effect of Acquisition on Mortality. Antimicrob. Agents Chemother. 52: 1028-1033 [Abstract] [Full Text]  
• Schwaber, M. J., Carmeli, Y. (2007). Mortality and delay in effective therapy associated with extended-spectrum {beta}-lactamase production in Enterobacteriaceae bacteraemia: a systematic review and meta-analysis. J Antimicrob Chemother 60: 913-920 [Abstract] [Full Text]  
• Pallecchi, L., Bartoloni, A., Fiorelli, C., Mantella, A., Di Maggio, T., Gamboa, H., Gotuzzo, E., Kronvall, G., Paradisi, F., Rossolini, G. M. (2007). Rapid Dissemination and Diversity of CTX-M Extended-Spectrum {beta}-Lactamase Genes in Commensal Escherichia coli Isolates from Healthy Children from Low-Resource Settings in Latin America. Antimicrob. Agents Chemother. 51: 2720-2725 [Abstract] [Full Text]  
• Tumbarello, M., Sanguinetti, M., Montuori, E., Trecarichi, E. M., Posteraro, B., Fiori, B., Citton, R., D'Inzeo, T., Fadda, G., Cauda, R., Spanu, T. (2007). Predictors of Mortality in Patients with Bloodstream Infections Caused by Extended-Spectrum-{beta}-Lactamase-Producing Enterobacteriaceae: Importance of Inadequate Initial Antimicrobial Treatment. Antimicrob. Agents Chemother. 51: 1987-1994 [Abstract] [Full Text]  
• Jorgensen, C. J., Cavaco, L. M., Hasman, H., Emborg, H.-D., Guardabassi, L. (2007). Occurrence of CTX-M-1-producing Escherichia coli in pigs treated with ceftiofur. J Antimicrob Chemother 59: 1040-1042 [Full Text]  
• DeRyke, C. A., Banevicius, M. A., Fan, H. W., Nicolau, D. P. (2007). Bactericidal Activities of Meropenem and Ertapenem against Extended-Spectrum-{beta}-Lactamase-Producing Escherichia coli and Klebsiella pneumoniae in a Neutropenic Mouse Thigh Model. Antimicrob. Agents Chemother. 51: 1481-1486 [Abstract] [Full Text]  
• Tofteland, S., Haldorsen, B., Dahl, K. H., Simonsen, G. S., Steinbakk, M., Walsh, T. R., Sundsfjord, A., the Norwegian ESBL Study Group, (2007). Effects of Phenotype and Genotype on Methods for Detection of Extended-Spectrum-{beta}-Lactamase-Producing Clinical Isolates of Escherichia coli and Klebsiella pneumoniae in Norway. J. Clin. Microbiol. 45: 199-205 [Abstract] [Full Text]